Description

DX600 TFA is a selective ACE2 specific inhibitor (KD: 1.3 nM), and does not cross-react with ACE. DX600 TFA exacerbates diabetes-induced cardiovascular dysfunction and the increase in cardiac and renal NOX activity[1][2][3].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)–Metabolism-protein/nucleotide metabolism–C141H185N35O40S2.xC2HF3O2—-[1]Liao K, et al. Development of an enzymatic assay for the detection of neutralizing antibodies against therapeutic angiotensin-converting enzyme 2 (ACE2).J Immunol Methods. 2013 Mar 29;389(1-2):52-60. |[2]Yousif MH, et al. Characterization of Angiotensin-(1-7) effects on the cardiovascular system in an experimental model of type-1 diabetes. Pharmacol Res. 2012 Sep;66(3):269-75. |[3]Svilenov HL, et al. Extrinsic stabilization of antiviral ACE2-Fc fusion proteins targeting SARS-CoV-2. Commun Biol. 2023 Apr 8;6(1):386. |[4]Joshi S, et al. Angiotensin converting enzyme versus angiotensin converting enzyme-2 selectivity of MLN-4760 and DX600 in human and murine bone marrow-derived cells. Eur J Pharmacol. 2016 Mar 5;774:25-33. |[5]Fraga-Silva RA, et al. ACE2 activation promotes antithrombotic activity. Mol Med. 2010 May-Jun;16(5-6):210-5. —-3074.33 (free acid)–99.94–[Ac-GDYSHCSPLRYYPWWKCTYPDPEGGG-NH2 ( Disulfide bridge: Cys6-Cys17) (TFA)]–Metabolic Disease; Cardiovascular Disease–H2O : 100 mg/mL (ultrasonic)–Angiotensin-converting Enzyme (ACE)—-Metabolic Enzyme/Protease–Peptides